News
AASLD debrief: Five drugs show promise in NAFLD (and two do not)
BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...
News
Rituximab tops azathioprine for relapsing ANCA-associated vasculitis remission maintenance
ATLANTA – The RITAZAREM trial results provide evidence that rituximab provides superior maintenance of remission in patients with relapsing...
Article
Symmetric hair loss across frontal and temporal scalp
Article
Keeping Lesions at Arm’s Length
News
Newborns’ maternal protection against measles wanes within 6 months
Despite findings of infants’ high susceptibility to measles as early as 3 months old, current epidemiological evidence does not support changes in...
Article
Menopause
This clinical puzzle is based on Kaunitz AM, McCullough DC. 2019 Update on menopause. OBG Management. 2019;31(6):21-22,24,30-31,e53.
Article
Firm and tender growth in right nostril
News
Vaping front and center at Hahn’s first FDA confirmation hearing
Stephen Hahn, MD, President Trump’s pick to head the Food and Drug Administration, faced questions from both sides of the aisle on youth vaping,...
Article
Scalp Psoriasis: A Challenge for Patients and Dermatologists
More than 80% of patients with psoriasis have scalp involvement at some point during the course of their...
News
TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off
BOSTON – With no approved pharmacologic treatments for NAFLD and NASH, weight reduction remains one of the mainstays of treatment.